Clinical Trial Update: Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/2 study evaluating Radium-223 dichloride in combination with Bortezomib and Dexamethasone for relapsed multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Velcade (bortezomib)
• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: WITHDRAWN